全文获取类型
收费全文 | 7873篇 |
免费 | 597篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 286篇 |
妇产科学 | 208篇 |
基础医学 | 1081篇 |
口腔科学 | 226篇 |
临床医学 | 828篇 |
内科学 | 1701篇 |
皮肤病学 | 109篇 |
神经病学 | 712篇 |
特种医学 | 162篇 |
外科学 | 873篇 |
综合类 | 118篇 |
一般理论 | 6篇 |
预防医学 | 877篇 |
眼科学 | 151篇 |
药学 | 568篇 |
2篇 | |
中国医学 | 36篇 |
肿瘤学 | 484篇 |
出版年
2023年 | 96篇 |
2022年 | 64篇 |
2021年 | 285篇 |
2020年 | 212篇 |
2019年 | 262篇 |
2018年 | 288篇 |
2017年 | 217篇 |
2016年 | 176篇 |
2015年 | 204篇 |
2014年 | 285篇 |
2013年 | 416篇 |
2012年 | 586篇 |
2011年 | 557篇 |
2010年 | 319篇 |
2009年 | 286篇 |
2008年 | 442篇 |
2007年 | 487篇 |
2006年 | 382篇 |
2005年 | 371篇 |
2004年 | 374篇 |
2003年 | 341篇 |
2002年 | 297篇 |
2001年 | 96篇 |
2000年 | 79篇 |
1999年 | 79篇 |
1998年 | 43篇 |
1997年 | 45篇 |
1996年 | 37篇 |
1995年 | 32篇 |
1994年 | 40篇 |
1993年 | 38篇 |
1992年 | 67篇 |
1991年 | 67篇 |
1990年 | 61篇 |
1989年 | 54篇 |
1988年 | 56篇 |
1987年 | 61篇 |
1986年 | 47篇 |
1985年 | 46篇 |
1984年 | 37篇 |
1983年 | 52篇 |
1982年 | 27篇 |
1980年 | 25篇 |
1979年 | 27篇 |
1978年 | 24篇 |
1976年 | 24篇 |
1974年 | 28篇 |
1973年 | 22篇 |
1970年 | 29篇 |
1969年 | 28篇 |
排序方式: 共有8490条查询结果,搜索用时 15 毫秒
1.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
2.
Megan Smith-Uffen Nicci Bartley Grace Davies Megan Best 《Patient education and counseling》2021,104(6):1325-1334
ObjectivesSingle-gene testing is associated with psycho-social challenges for cancer patients. Genomic testing may amplify these. The aim of this study was to understand patients’ motivations and barriers to pursue cancer genomic testing, to enable healthcare providers to support their patients throughout the testing process and interpretation of test results.MethodsFive databases were searched for original peer reviewed research articles published between January 2001 and September 2018 addressing motivation for genomic cancer testing. QualSyst was used to assess quality.Results182 studies were identified and 17 were included for review. Studies were heterogenous. Both somatic and germline testing were included, and 14 studies used hypothetical scenarios. 3249 participants were analyzed, aged 18 to 94. Most were female and white. The most common diagnoses were breast, ovarian, lung and colorectal cancer. Interest in testing was high. Motivations included ability to predict cancer risk, inform disease management, benefit families, and understand cancer. Barriers included concerns about cost, privacy/confidentiality, clinical utility, and psychological harm.ConclusionsDespite concerns, consumers are interested in cancer genomic testing if it can provide actionable results for themselves and their families.Practice ImplicationsProviders must manage understanding and expectations of testing and translate genetic information into health-promoting behaviours. 相似文献
3.
Combs Katie Massey Buckley Pamela R. Lain Marion Amanda Drewelow Karen M. Urano Grace Kerns Suzanne E. U. 《Prevention science》2022,23(6):969-981
Prevention Science - As evidence-based interventions (EBIs) become more widely disseminated, fidelity of implementation (FOI) often wanes. This study explores the association between FOI and... 相似文献
4.
Bernard Natukunda Grace Ndeezi Lay See Er Francis Bajunirwe Gayle Teramura Meghan Delaney 《ISBT科学丛刊》2019,14(4):366-373
5.
6.
Nicole L. Stout DPT Justin C. Brown PhD Anna L. Schwartz PhD FNP Timothy F. Marshall PhD Anna M. Campbell PhD MBE Larissa Nekhlyudov MD MPH David S. Zucker MD PhD Karen M. Basen-Engquist PhD MPH Grace Campbell PhD MSW RN Jeffrey Meyerhardt MD MPH Andrea L. Cheville MD MSSE Kelley R. Covington MS Jennifer A. Ligibel MD Jonas M. Sokolof DO Kathryn H. Schmitz PhD MPH Catherine M. Alfano PhD 《Cancer》2020,126(12):2750-2758
7.
Major depressive disorder is a debilitating disorder affecting millions of people each year. Brain-derived neurotrophic factor (BDNF) and inflammation are two prominent biologic risk factors in the pathogenesis of depression that have received considerable attention. Many clinical and animal studies have highlighted associations between low levels of BDNF or high levels of inflammatory markers and the development of behavioral symptoms of depression. However, less is known about potential interaction between BDNF and inflammation, particularly within the central nervous system. Emerging evidence suggests that there is bidirectional regulation between these factors with important implications for the development of depressive symptoms and anti-depressant response. Elevated levels of inflammatory mediators have been shown to reduce expression of BDNF, and BDNF may play an important negative regulatory role on inflammation within the brain. Understanding this interaction more fully within the context of neuropsychiatric disease is important for both developing a fuller understanding of biological pathogenesis of depression and for identifying novel therapeutic opportunities. Here we review these two prominent risk factors for depression with a particular focus on pathogenic implications of their interaction. 相似文献
8.
9.
10.
Grace G. Wong Vincent Ha Michael P. Chu Deonne Dersch-Mills Sunita Ghosh Carole R. Chambers Michael B. Sawyer 《Clinical colorectal cancer》2019,18(1):72-79